Boston upstart Acetylon Pharmaceuticals has raised $12.4 million in new venture funds, according to MassHighTech. Citing SEC documents the news service revealed that Acetylon is in the process of raising a $30 million round to back its work developing HDAC inhibitors for inflammatory and neurological diseases as well as cancer. Its technology builds on the work of four top scientists at Dana-Farber Cancer Institute and Harvard University. Story